"FDA's primary guardrail, the confirmatory trial, has been limited in execution." Sarepta preliminary Q4 revenue beats, but full year just misses ...

Sarepta Therapeutics' Elevidys for DMD shows ... We should also note the fact that Elevidys ultimately failed to meet the primary endpoint in its pivotal EMBARK study (although it did meet all ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

--(BUSINESS WIRE)--Sarepta Therapeutics ... EMERGENE is a global study, and the primary endpoint is the biomarker expression of beta-sarcoglycan protein, the absence of which is the sole cause ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

Sarepta Therapeutics has followed through on ... to intervene with urgency on behalf of the children we serve." The primary endpoint for EMBARK is the assessment of the change in NSAA score ...

Sarepta’s gene therapy for Duchenne muscular ... The outcome of the review was not certain, given that Elevidys was unable to meet its primary objective in the phase 3 EMBARK study reported ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT ... who were not the primary focus of Elevidys’ clinical trials, further supports Kapoor ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. Solid Biosciences advances ...

"FDA's primary guardrail, the confirmatory trial, has been limited in execution." Seeking Alpha has reached out to Sarepta and Biogen for comment but has yet to hear back from either.